Answers are grounded in this paper and cite their sources.
T cells, consistent with CTLA-4 blockade, while maintaining substantially lower systemic antibody levels than systemic ipilimumab. Although this model does not permit comprehensive assessment of long-term secretion or toxicity, these data support the feasibility and biological activity of localized anti-CTLA-4 delivery and highlight a controllable, retrievable platform to reduce systemic exposure.
No takes yet. Share an insight, caveat, or question.
Engel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: